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Abstract
There is still no consensus on the follow-up frequency 
and regimen after curative resection for gastric 
cancer. Moreover, controversy exists regarding the 
utility of follow-up in improving survival, and the 
recommendations of experts and societies vary 
considerably. The main reason to establish surveillance 
programs is to diagnose tumor recurrence or meta-
chronous cancers early and to thereby provide prompt 
treatment and prolong survival. In the setting of 
gastric malignancies, other reasons have been put 
forth: (1) the detection of adverse effects of a previous 
surgery, such as malnutrition or digestive sequelae; 
(2) the collection of data; and (3) the identification of 
psychological and/or social problems and provision of 
appropriate support to the patients. No randomized 
controlled trials on the role of follow-up after curative 
resection of gastric carcinoma have been published. 
Herein, the primary retrospective series and systematic 
reviews on this subject are analyzed and discussed. 
Furthermore, the guidelines from international and 
national scientific societies are discussed. Follow-
up is recommended by the majority of institutions; 
however, there is no real evidence that follow-up can 
improve long-term survival rates. Several studies have 
demonstrated that it is possible to stratify patients 
submitted to curative gastrectomy into different classes 
according to the risk of recurrence. Furthermore, 
promising studies have identified several molecular 
markers that are related to the risk of relapse and 
to prognosis. Based on these premises, a promising 
strategy will be to tailor follow-up in relation to the 
patient and tumor characteristics, molecular marker 
status, and individual risk of recurrence.
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Core tip: There is still no consensus on the utility, 
frequency and regimen of follow-up after curative 
resection for gastric cancer. Surveillance programs 
may allow the following: (1) the early diagnosis of 
recurrence; (2) the detection of adverse effects of a 
previous surgery; (3) the collection of data; and (4) the 
detection of psychological and social problems. This 
editorial discusses the main studies, systematic reviews 
and guidelines on this subject. Several studies have 
demonstrated that patients may be stratified according 
to the risk of recurrence. A promising strategy will be 
to tailor follow-up in relation to the patient and tumor 
characteristics, molecular marker status, and individual 
risk of recurrence.
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cancer: Is it time to tailor it? World J Gastroenterol 2017; 
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com/1007-9327/full/v23/i19/3379.htm  DOI: http://dx.doi.
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INTRODUCTION
The main goal of follow-up programs after curative 
surgery is the early detection of cancer recurrence, 
such that rapid and efficacious treatment may 
be administered and long-term survival may be 
improved[1]. Other objectives of follow-up are to identify 
treatment-related complications and to collect data 
concerning cancer history and treatment outcomes[2]. 
International guidelines recommend postoperative 
follow-up for the majority of cancers, even if the role 
of follow-up in improving overall survival has not been 
demonstrated for all types of tumors. 
According to the GLOBOCAN data, gastric cancer 
represents the fifth most common malignancy in the 
world, with 952000 new cases estimated to have 
occurred in 2012. Stomach cancer is the third leading 
cause of cancer death in both sexes worldwide, with 
an estimated 723000 deaths in 2012[3]. In the United 
States, there were an estimated 26370 cases in 2016, 
with 10730 deaths[4]. 
Recurrence occurs within the first 3 years in the 
majority of cases, and fewer than 10% of recurrences 
occur after 5 years[1,5,6]. Survival after recurrence 
is poor, and in the majority of recurrence cases, 
potentially curative treatments are not possible[1,7]. 
There is still no consensus on the frequency and 
regimen of follow-up after curative resection. Moreover, 
controversy exists regarding the utility of follow-up 
in improving survival, and the recommendations of 
experts and societies vary considerably. The problem of 
cost-effectiveness has also been raised[8]. The objective 
of this editorial is to review the current literature 
concerning follow-up after curative resection for cancer. 
We discuss the rationale of follow-up, the methods of 
follow-up, including clinical examination, biochemical 
analyses and radiological tools to detect gastric 
cancer recurrence, the main articles evaluating the 
role of follow-up in improving overall survival and the 
current guidelines of the most important international 
societies. Furthermore, the role of molecular analysis 
in predicting gastric cancer recurrence is analyzed, and 
future directions of research are suggested. 
RATIONALE OF FOLLOW-UP 
The main reason to establish surveillance programs 
after curative gastrectomy is to diagnose tumor 
recurrence or metachronous cancers early to thereby 
provide prompt treatment and prolong patient 
survival. In the setting of gastric malignancies, other 
reasons have been advocated, including (1) the 
detection of adverse effects of a previous surgery, 
such as vitamin and iron depletion or malnutrition 
or digestive sequelae[9]; (2) the collection of data to 
evaluate the efficacy and outcomes of treatments; 
and (3) the detection of psychological and/or social 
problems subsequent to the disease and the provision 
of appropriate support to the patients[10].
Gastric cancer recurrence may be classified into 
five patterns[11-14]. The first is the locoregional pattern, 
defined as tumor relapse at the resection margin 
(proximal, including the esophagus or the proximal 
stomach, and distal, including the duodenal stump) 
or in the adjacent tissue of the surgical bed. The 
second is the nodal pattern, which is relapse within 
the regional and distant lymph nodes, including the 
retropancreatic, retrocrural and para-aortic nodes. 
The third pattern is peritoneal recurrence, with 
intraperitoneal tumor spread. The fourth pattern is 
hematogenous relapse, defined as metastatic lesions 
in distant organs (e.g., liver, lung, or bones). Finally, 
some tumors have a mixed pattern of recurrence, 
including different synchronous routes of relapse.
The majority of patients relapse within the first 3 
years, with a median time to recurrence ranging from 
14 to 29 mo in recent series[13-17]. After laparoscopic 
gastrectomy, similar times to recurrence and patterns 
have been demonstrated[16,17].
Among clinicopathological prognostic factors, the 
Italian Research Group for Gastric Cancer identified 
nodal status, nodal ratio, and stage, and proposed a 
prognostic score that was able to predict the likelihood 
of recurrence for high-risk patients better than the 
TNM stage[14].  
The majority of gastric cancer recurrences are 
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not surgically curable. The majority of patients with 
liver metastases are not candidates for resection, and 
treatment for peritoneal carcinosis is experimental[18,19]. 
Chemotherapy is the primary treatment for recurrent 
gastric carcinoma and may prolong survival and 
improve the quality of life. The median survival with 
chemotherapy is poor, ranging from 6 to 13 mo[13-21]. 
Follow-up also plays a role in evaluating and treating 
the long-term adverse effects of gastrectomy[1]. Proper 
follow-up allows the detection of digestive problems, 
such as dyspepsia, nausea, vomiting, early satiety, 
reflux, and anorexia, which occur in approximately 
30% of patients. Furthermore, postgastrectomy 
syndromes, such as dumping syndrome, bile reflux, 
Roux-en-Y stasis syndrome and afferent and efferent 
loop syndromes, can be identified and treated[22]. 
Malabsorption may cause iron deficiency anemia 
(approximately 30% of patients), megaloblastic anemia 
due to vitamin B12 deficiency, and bone diseases 
(osteopenia, osteoporosis)[23,24].
METHODS OF FOLLOW-UP 
Follow-up is based on the case history, clinical exami-
nation, blood tests, including tumor marker assays, 
imaging and endoscopy.
Tumor markers
The level of tumor markers is commonly used during 
follow-up because the assay is simple and inexpensive 
to perform[25,26]. However, the specificity and sensitivity 
are low. Markers are less useful in patients without an 
increase in the preoperative level of a tumor marker. 
As reported by Takahashi et al[27] 54.7% of patients 
had a first-time increase in carcinoembryonic antigen 
(CEA) levels at recurrence, and 40% had a first-time 
increase in carbohydrate antigen 19-9 (CA19-9) at 
recurrence. In that study, the sensitivity of the two 
markers for recurrence was 85.0%[27]. In contrast, 
when the preoperative level of CEA was elevated, the 
CEA level increased again at the time of recurrence in 
more than 90% of patients. Additionally, the CA19-9 
level increased again at recurrence in more than 90% 
of patients who had high preoperative levels[27]. In a 
study by Kim et al[28] on 1117 patients, CEA and/or 
CA72-4 were found to be independent risk factors 
for recurrence. According to the findings of Choi 
et al[29], increased CEA was more frequent in cases 
of liver recurrence, whereas increased CA 19-9 was 
more frequent in cases of peritoneal recurrence. 
Furthermore, it has been reported that the elevation 
of tumor markers occurs earlier than imaging 
abnormalities (approximately 2-5 mo)[27,30].
Endoscopic surveillance
Endoscopic surveillance aims to detect intraluminal 
recurrence, metachronous tumoral lesions, pre-
cancerous gastric stump diseases and anastomotic 
strictures. The role of endoscopic surveillance is 
fundamental after the endoscopic treatment of 
early gastric cancer. Hahn and colleagues reviewed 
a series of 1347 patients who underwent curative 
endoscopic submucosal dissection (ESD) for early 
gastric cancer[31]. These authors found an annual 
incidence of recurrence of 0.84% at the previous 
endoscopic resection site and 2.48% at other sites in 
the stomach. Surveillance endoscopy at an interval 
of ≤ 12 mo permitted the detection of lesions at an 
earlier stage[31]. For these reasons, the majority of 
authors recommend endoscopy exams with short 
time intervals after the endoscopic resection of early 
stage gastric cancer[32]. The incidence of gastric stump 
recurrence or metachronous cancer ranges between 
1% and 7% depending on the study and geographical 
area[33]. The time to the development of tumoral 
lesions in the remnant stomach is variable, ranging 
from months to decades[34]. Endoscopic surveillance 
may allow early diagnosis and potentially curative 
treatment, with survival advantages for resectable 
patients[35]. 
Imaging modalities 
Computed tomography (CT) represents the most-used 
imaging technique for the surveillance of patients with 
previous gastric cancer. However, only a few studies 
have evaluated the ability of CT to detect recurrence 
after gastrectomy. The accuracy is reported to be 
approximately 60%-70%, with a low predictive value 
in cases of peritoneal recurrence[36]. Many reports 
have investigated the role of positron emission 
tomography (PET)/CT[37-40]. One meta-analysis[37] that 
included fourteen studies (828 patients) has shown 
the usefulness of PET/CT in this setting: the pooled 
sensitivity, specificity, positive likelihood ratio, negative 
likelihood ratio and diagnostic odds ratio of 18F-fluoro-
2-deoxy-D-glucose PET (18F-FDG PET) or PET/CT were 
0.85 (95%CI: 0.75-0.92), 0.78 (95%CI: 0.72-0.84), 3.9 
(95%CI: 2.9-5.4), 0.19 (95%CI: 0.11-0.34), and 21 
(95%CI: 9-47), respectively. On a per-lesion basis, the 
pooled sensitivity was 0.75 (95%CI: 0.61-0.86). The 
area under the SROC curve of PET/CT per patient was 
0.86. 
One study compared CT and PET/CT during 
the follow-up of 139 patients, 28 of whom had 
recurrence[41]. The authors did not find statistically 
significant differences between the sensitivity, specificity 
and accuracy of PET/CT (53.6%, 84.7%, and 78.4%, 
respectively) and those of CT (64.3%, 86.5%, and 
82.0%, respectively) for detecting tumor recurrence, 
except in the detection of peritoneal carcinomatosis. 
Among 36 recurrent lesions, 8 lesions (22.2%) were 
detected only with PET/CT, and 10 lesions (27.8%) 
were detected only with CT. PET/CT detected secondary 
malignancies in 8 patients. According to this study, 
additional PET/CT or CT scans may improve the 
detection rate of tumor recurrence and provide other 
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the two groups (43% vs 34% at 5 years for inten-
sive and standard follow-up, respectively, P = 0.36). 
The second study was published in 2003 by Kodera 
et al[48] from Nagoya. This retrospective study included 
211 patients with relapsing gastric cancer, treated 
between 1985 and 1996. In this analysis, patients 
were divided into groups with and without cancer-
related symptoms at the time the recurrent disease 
was diagnosed. Survival was analyzed in these two 
groups. The follow-up program consisted of an interim 
history, physical examinations, blood tests and tumor 
marker assays, repeated every 3 mo for the first 
postoperative year and every 6 mo thereafter for at 
least 5 years. Either abdominal ultrasonography or CT 
was performed every 6 mo, as was chest radiography. 
Endoscopy was performed annually to screen for 
cancer in the gastric remnant, beginning 1 to 1.5 
years after surgery. In addition to this regular follow-
up, patients consulted their doctors whenever the 
patients had clinical symptoms. Eighty-eight (45%) 
patients were asymptomatic at the time of diagnosis 
of a recurrence, whereas 109 had symptoms and 
consulted the physician or reported the symptoms 
during a scheduled follow-up. A greater proportion 
of the patients with asymptomatic recurrence was 
treated with chemotherapy and underwent resection 
of metastatic lesions (although these data were not 
statistically significant). Survival after the diagnosis 
of recurrent disease was better when the recurrence 
was detected at an asymptomatic stage (P = 0.0001). 
Longer survival in patients with asymptomatic re-
currences was observed even in patients whose 
recurrences were not treated with chemotherapy. 
However, because symptomatic recurrences were 
diagnosed later after surgery than were asymptomatic 
recurrences, the overall survival after curative 
resection of the primary tumor was not significantly 
affected by the presence or absence of symptoms at 
the time of cancer recurrence. The authors conclude 
that the early detection of asymptomatic gastric cancer 
recurrence did not improve the overall survival of 
patients with recurrence after curative resection. Until 
the development of a more effective treatment for this 
disease, close follow-up may offer no survival benefit. 
Both of these studies and, consequently, the systematic 
review (the conclusions of which are based on these 
two articles) have several limitations: the retrospective 
nature of the studies, the period of treatment (prior to 
2000), the protocol and administration of perioperative 
treatment, and the obsolescence of imaging modalities 
to detect recurrence. 
The most recent studies report interesting results. 
Park et al[49] in 2016 reviewed the clinical data of 376 
patients with intra-abdominal recurrence after curative 
gastrectomy. These patients were classified according 
to the surveillance interval. A total of 101 patients 
(26.9%) composed the 3 mo or less group, while 
137 (36.4%) composed the 3- to 6-mo group, and 
108 (28.7%) composed the 6- to 12-mo group. The 
critical information, such as an unexpected secondary 
malignancy. Integrated PET/CT has an accuracy ranging 
from 75% to 97%. However, with both CT and PET, 
the accuracy is lower for detecting peritoneal disease. 
Inoue et al[42] have proposed the use of second-look 
laparoscopy and have shown that this approach is 
feasible in patients at a high risk of relapse.
WHAT IS THE EVIDENCE? 
No randomized controlled trials have been published 
on the role of follow-up after the curative resection of 
gastric carcinoma, and there is no proven evidence 
that follow-up can provide a survival advantage due 
to the early identification and treatment of tumor 
recurrence. 
Cardoso et al[43] published a systematic review on 
this topic in 2012. In this study, the authors searched 
the literature from 1999 to 2009 and selected five 
retrospective studies that reported data on follow-
up after gastric resection and included a total of 
810 patients[44-48]. Follow-up was performed using 
several modalities, including the following: history and 
physical examination, abdominal ultrasonography, 
CT, endoscopy, endoscopic ultrasound (EUS), chest 
radiography, blood counts, chemistry profile, tumor 
marker assays, barium enema, and bone scintigraphy. 
Only one study reported that DFS was significantly 
shorter in the intensive follow-up group than in the 
standard follow-up group (11.5 mo vs 19.2 mo, P 
= 0.02)[44]. In the included studies, survival post-
recurrence was significantly longer in the asymptomatic 
than in the symptomatic patients. However, no 
significant differences were found concerning overall 
survival according to the two studies reporting the 
information. Therefore, the authors of the systematic 
review concluded that there is no evidence that follow-
up may provide any survival benefit after gastric cancer 
resection and that further prospective studies are 
required to determine whether a subgroup of patients 
may benefit from more intensive follow-up. 
Two studies included in the review reported data 
on overall survival according to follow-up intensity. The 
first, a retrospective study by Tan et al[44] was published 
in 2007 and included the data from 102 patients 
submitted to curative gastrectomy in Singapore from 
1995 to 1998. Forty-nine patients were intensively 
followed-up, whereas 53 received the standard follow-
up. Intensive follow-up was defined as employing 
regular physical examinations, serum tumor marker 
assays and performing CT scans more than once 
every 12 mo. The preoperative characteristics of the 
patients in the two groups were similar. Neoadjuvant 
therapy was not administered, and adjuvant therapy 
was administered to 36 patients, 30 in the intensive 
follow-up group and 6 in the standard group (P < 
0.01). Recurrences were detected significantly earlier 
in the intensive follow-up group. However, no signifi-
cant difference in overall survival was found between 
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remaining 30 patients (8%) with a surveillance interval 
longer than 12 mo were excluded. The 3 mo or less 
group and the 3- to 6-mo group had higher proportions 
of stage 3 cancers and early recurrences within 24 
mo after gastrectomy than did the 6- to 12-mo group 
[stage 3 cancer: 87.1% (3 mo) vs 81.0% (3-6 mo) vs 
60.2% (6-12 mo), P < 0.001]. The recurrence rates 
within 24 mo after gastrectomy were 86.1% (3 mo) 
vs 78.8% (3-6 mo) vs 57.4% (6-12 mo) (P < 0.001). 
The proportion of patients with symptoms at the time 
of recurrence did not differ among the three groups (P 
= 0.122). The post-recurrence survival did not differ 
among the three groups (P = 0.057). According to the 
authors, although the detection of recurrence before 
symptoms enabled the prolongation of both post-
recurrence survival and overall survival, shortening the 
surveillance interval to less than 6 mo was not useful in 
improving survival. 
In 2016, Fujiya et al[50] retrospectively analyzed 
218 patients with recurrent gastric cancer after 
curative gastrectomy. The patients were divided into 
an asymptomatic group (n = 117) and a symptomatic 
group (n = 101). Peritoneal recurrence was less 
frequent in the asymptomatic group (22.2%) than in 
the symptomatic group (62.4%). 
The median time to recurrence was shorter in 
the asymptomatic group than in the symptomatic 
group (12.7 mo vs 18.9 mo, P < 0.001), and the 
median survival time after recurrence was longer in 
the asymptomatic group than in the symptomatic 
group (18.7 mo vs 7.5 mo, respectively, P < 0.001). 
The median overall survival time after gastrectomy 
was not significantly different between the groups 
(30.1 mo for asymptomatic recurrence vs 30.0 mo for 
symptomatic recurrence, P = 0.132). In a multivariate 
analysis, the overall survival after gastrectomy was not 
significantly different between the groups (HR = 0.86, 
P = 0.402). Among the patients with a nonperitoneal 
recurrence, the time to recurrence was similar between 
the asymptomatic and symptomatic groups (12.2 mo 
vs 15.2 mo, P = 0.062), but the survival time after 
recurrence was significantly longer in the asymptomatic 
group than in the symptomatic group (20.8 mo vs 
7.5 mo, P < 0.001). The overall survival time after 
gastrectomy was significantly greater in asymptomatic 
patients with nonperitoneal recurrence than in 
symptomatic patients (35.9 mo vs 24.0 mo, P = 0.039). 
According to this study, the detection of nonperitoneal 
recurrence before the appearance of symptoms may 
provide a survival benefit, and regular follow-up is 
recommended.
Lee et al[51] analyzed the data of 192 cancer patients 
with gastric cancer recurrence after curative resection. 
Of these patients, 126 (65.6%) had asymptomatic 
recurrences. The patients were divided into two groups: 
asymptomatic and symptomatic recurrence. The 
median recurrence-free survival did not differ between 
the two groups (P = 0.507), whereas the median post-
recurrence (P < 0.001) and overall survival times (P 
= 0.022) were longer in the asymptomatic group, 
suggesting the utility of follow-up programs.
In 2005, Marrelli et al[52] proposed a scoring system 
to predict recurrence in patients with previous gastric 
cancer, with the aim of identifying the categories of 
patients at higher risk. These authors demonstrated 
that the risk of recurrence increased remarkably 
with the score values; the risk of recurrence was 
only 5% in patients with a score below 10 and rose 
to 95.4% in patients with a score of 91 to 100. Their 
model correctly predicted recurrence in 227 of 272 
patients (sensitivity, 83.5%), whereas the absence 
of recurrence was correctly predicted in 214 of 264 
patients (specificity, 81.1%); the overall accuracy was 
82.2%. This scoring system was further validated with 
a group of 635 patients from 5 Italian Research Group 
for Gastric Cancer (GIRCG) centers[53]. In the validation 
group, the observed recurrence rates ranged from 
5% to 92% in the different scoring strata. The area 
under the receiver operating characteristic curve was 
0.889 (95%CI: 0.864-0.914; P < 0.001), indicating a 
high discrimination value of the score for recurrence. 
A good calibration was observed by comparing the 
predicted risk with the actual risk of recurrence. With 
a score cut-off value of 50, the sensitivity, specificity, 
and overall accuracy were 74%, 86%, and 81%, 
respectively. An inverse correlation between the time 
to recurrence and score level was also estimated (R2 = 
0.119, P < 0.001). In addition, Barchi et al[14] validated 
this scoring system on 185 patients with gastric cancer 
who underwent an operation with the intention of a 
cure, demonstrating that the GIRCG’s prognostic score 
was more accurate than the TNM system in predicting 
recurrence mainly for high-risk patients, whereas the 
score did not have the same effectiveness for low-risk 
patients and overestimated the chance of recurrence 
even for disease-free patients.
A final study from Baiocchi et al[54] included 814 
patients with recurrent cancer. Ninety-four percent had 
recurrence within 2 years, and 98% had recurrence 
within 3 years. In this study, thoracoabdominal CT and 
18F-FDG PET detected more than 90% of recurrences, 
whereas abdominal ultrasound detected 70%, and 
tumor marker assays detected 40%. Less than < 
10% of tumor relapses were identified by physical 
examination, chest X-ray, and upper gastrointestinal 
(GI) endoscopy. Twenty-six percent of patients with 
recurrence were treated, but only 3.2% were treated 
with the intention of a cure. On the basis of these 
results, the authors affirmed that follow-up should 
be focused on the first 3 years and based mainly on 
thoracoabdominal CT and 18F-FDG PET.
GUIDELINES
Different protocols have been proposed by scientific 
societies and groups. The lack of strong evidence is 
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responsible for the heterogeneity of the guidelines. 
NCCN 
The NCCN recommends a systematic follow-up for all 
patients. A history and physical examination should be 
undertaken every 3 to 6 mo for 1 to 2 years, every 6 
to 12 mo for 3 to 5 years, and annually thereafter[55]. 
However, a CBC, a chemistry profile, radiologic imaging, 
or upper GI endoscopy should be performed if clinically 
indicated. Monitoring and treatment of vitamin B12 and 
iron deficiency is recommended in surgically resected 
patients. 
ESMO 
ESMO recommends regular follow-up for the in-
vestigation and treatment of symptoms related to 
previous treatments, for psychological support and 
for the early detection of recurrence[56]. A follow-
up tailored to the individual patient and the stage of 
the disease is recommended. Furthermore, ESMO 
recommends dietary support for patients on either a 
radical treatment or palliative pathway with reference 
to vitamin and mineral deficiencies. If relapse or 
disease progression is suspected, then a clinical 
history, a physical examination and directed blood 
tests should be conducted. 
Association of upper gastrointestinal surgeons 
of Great Britain and ireland, the british society of 
gastroenterology and the british association of surgical 
oncology
A regular review of patients following the treatment 
of esophageal and gastric cancer is recommended 
for symptom management, supportive care and 
surveillance. These organizations assert that although 
regular review may identify an early recurrence, there 
is no evidence for specific investigations or that such 
an approach can affect OS[57].
GIRCG 
The GIRCG recommends routine follow-up for all patients 
for the following reasons: oncological (detection and 
management of cancer recurrence), gastroenterolo-
gical (endoscopic surveillance and management of 
postgastrectomy symptoms), research (the collection 
of data on treatment toxicity, time to and site of 
recurrence, and survival and cost-benefit analyses), 
and pastoral (psychological and emotional support)[58]. 
The nutritional sequelae of gastrectomy, including, but 
not limited to, adequate vitamin B12 and iron, and 
calcium replacement should be investigated. Follow-up 
should be offered by members of the multidisciplinary 
team who managed the initial diagnosis, staging, and 
treatment, and modalities should be tailored to the 
individual patient, to the stage of their disease, and 
to the treatment options available. Cross-sectional 
imaging is recommended to detect asymptomatic 
recurrence. Upper GI endoscopy may be used to detect 
local recurrence or metachronous primary GC in 
patients who have undergone a subtotal gastrectomy. 
Routine screening for the asymptomatic recurrence of 
GC may be discontinued after 5 years, as recurrence 
beyond that interval is infrequent. 
French guidelines: HAS
The French Haute Autorite de Sante recommends 
follow-up to detect recurrent or metachronous cancer, 
symptoms and adverse effects of treatment, to control 
the quality of life and to provide supportive care and 
social assistance[59]. Follow-up is recommended for 
at least for 5 years by the multidisciplinary team that 
cared for the patient and, after this period, by the 
general practitioner. Clinical examinations should be 
performed every 3-6 mo during the first 1-3 years, 
every 6 mo for the first 5 years, and then, after 5 
years, performed once a year. Abdominal ultrasound 
or thoracoabdominal CT should be performed every 
6 mo for 3 years and then every year for 2 years. GI 
endoscopy should be performed in the case of remnant 
stomach and precancerous lesions or Helicobacter pylori 
infections on initial biopsies (frequence of endoscopy is 
not specified). Blood tests for tumor markers are not 
recommended. 
The American Society of Clinical Oncology and the 
Japanese Gastric Cancer Association have not provided 
guidelines for the follow-up of gastric cancer. 
MOLECULAR BIOMARKERS
Recent research on gastric cancer has focused on 
molecular biomarkers. Some markers have prognostic 
significance; other markers are potential targets 
for novel chemotherapeutics. In the setting of sur-
veillance, some of the biomarkers may represent 
potential prognostic indicators, able to differentiate 
patients according to the risk of recurrence, and 
potential early markers of tumor relapse. Among 
the prognostic markers, the expression of vascular 
endothelial growth factor, a regulator of angiogenesis, 
has been associated with a poor prognosis by several 
authors[60,61]. VEGF receptors are the targets of 
novel monoclonal antibodies that are currently being 
evaluated in clinical trials as potential treatments for 
advanced gastric cancer, such as ramucirumab and 
bevacizumab[62,63].
Several microRNAs, such as miR-328[64,65], have 
been found to be potential biomarkers for recurrence 
after curative resection, even though none are currently 
used in clinical practice. 
The hypermethylation of various genes, such as 
cadherin 1, E-cadherin, hMHL1 and others, has been 
associated with the prognosis of gastric cancer[66]. 
Among the cell cycle regulators, cyclin E is con-
sidered a significant regulatory factor and useful 
prognostic parameter in gastric cancers[67]. Alterations 
in the p53 gene are also associated with less favorable 
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prognoses in advanced gastric cancer[68]. Apoptosis-
related factors are associated with the prognosis of 
gastric cancer patients. Bcl-2 and Fas expression are 
related to the progression and prognosis of gastric 
carcinoma[69,70]. The expression of markers such as 
VEGF or Bcl-2 is analyzed in the surgical specimen 
and may permit a better stratification of the risk 
of recurrence. Blood circulating biomarkers, on the 
other hand, may be quantified during follow-up with 
specific blood tests. We must point out that for novel 
biomarkers, the validation of a prognostic role to 
detect recurrence in a large cohort is still required. 
Future studies will help to better characterize the 
role of each molecular factor and the ability of that 
marker to predict recurrence, allowing personalization 
of follow-up according to the individual risk of relapse.
CONCLUSION
Recommendations concerning the follow-up after 
curative resection of gastric cancer are heterogeneous, 
reflecting the absence of solid and high-grade 
evidence. The majority of international societies and 
authors recommend surveillance after gastrectomy on 
the basis of retrospective studies, although there is no 
consensus on how the follow-up should be conducted 
or how often the follow-ups should be scheduled. 
Surveillance permits the identification and treatment 
of postoperative digestive and nutritional problems, 
with a potential impact on quality of life. The ability of 
an early diagnosis to increase survival has not been 
demonstrated. Indeed, the outcomes after recurrence 
are poor according to the published series, even in 
cases of early diagnosis. The development of new 
agents based on new molecular targets may be a 
possible strategy to improve the survival of patients 
with recurrence. Several studies have demonstrated 
that it is possible to stratify patients submitted to 
curative gastrectomy into different classes according 
to the risk of recurrence. Prognostic scores may help 
clinicians to modulate the intensity and methods of 
surveillance. 
In the future, better characterization of the mole-
cular prognostic factors for gastric cancer will permit a 
better understanding of the biology of each resected 
gastric cancer and its risk of recurrence, enabling 
the establishment of a more individualized and 
tailored follow-up based on the tumor and patient 
characteristics. Tailoring the follow-up based on an 
accurate stratification of the recurrence risk may be 
a strategy to limit useless and expensive surveillance 
and to promptly identify recurrence patients who may 
benefit from treating the relapsing tumor, thereby 
improving survival outcomes.
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